Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Common Equity (2016 - 2025)

Historic Common Equity for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to $64.7 million.

  • Enanta Pharmaceuticals' Common Equity fell 4975.93% to $64.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.7 million, marking a year-over-year decrease of 4975.93%. This contributed to the annual value of $64.7 million for FY2025, which is 4975.93% down from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Common Equity stood at $64.7 million for Q3 2025, which was down 4975.93% from $79.3 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' 5-year Common Equity high stood at $436.0 million for Q1 2021, and its period low was $64.7 million during Q3 2025.
  • In the last 5 years, Enanta Pharmaceuticals' Common Equity had a median value of $237.8 million in 2023 and averaged $245.6 million.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Common Equity plummeted by 1027.98% in 2021, and later crashed by 4975.93% in 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Common Equity (Quarter) stood at $384.4 million in 2021, then decreased by 21.74% to $300.8 million in 2022, then plummeted by 36.22% to $191.9 million in 2023, then plummeted by 41.73% to $111.8 million in 2024, then crashed by 42.12% to $64.7 million in 2025.
  • Its Common Equity stands at $64.7 million for Q3 2025, versus $79.3 million for Q2 2025 and $93.5 million for Q1 2025.